MOTS-c Research: What the Studies Show
MOTS-c is a 16-amino-acid mitochondrial-derived peptide studied as a metabolic regulator and 'exercise mimetic'. The strongest data is animal and in-vitro, but human evaluation is now underway — here is each key study, in plain English.
Mechanism of action
MOTS-c is encoded inside the mitochondrial 12S rRNA region rather than in nuclear DNA, which places it in the small class of mitochondrial-derived peptides alongside humanin and the SHLP family.
Its described primary target is skeletal muscle, where it inhibits the folate-methionine cycle and activates AMPK — the same energy-sensing pathway that responds to exercise and caloric restriction.
Downstream signalling reported in the literature includes PGC-1α-linked mitochondrial bioenergetics, suppression of myostatin and FOXO1 transcription, activation of AKT/mTORC2, and reduced reactive oxygen species emission.
The studies
Each card names the model, species and design, and states clearly whether the finding comes from rodents, cell culture or humans.
Discovery & metabolic foundation
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis (Lee et al.)
Identifying MOTS-c and establishing what it does to metabolism.
Cell Metabolism · cell culture plus mouse models · age-dependent and high-fat-diet-induced obesity and insulin resistance endpoints
- Skeletal muscle
- Primary target tissue
- Folate-methionine cycle → AMPK
- Pathway
- Prevented in mice
- Diet-induced obesity
- The paper that first identified MOTS-c and set the entire research direction that followed.
- Administering the peptide prevented both age-dependent and high-fat-diet-induced obesity and insulin resistance in mice.
- It ties the metabolic effect to a specific, measurable mechanism — inhibition of the folate-methionine cycle leading to AMPK activation — rather than an unexplained outcome.
Exercise response, physical capacity & healthspan
MOTS-c is an exercise-induced regulator of age-dependent physical decline (Reynolds et al.)
Whether exercise raises MOTS-c naturally in humans, and whether giving it back improves physical capacity.
Nature Communications · human skeletal muscle biopsies and circulating levels around exercise · treatment in young, middle-aged and old mice · running performance and healthspan endpoints
- Endogenous MOTS-c rises
- Exercise effect in humans
- Improved at all ages
- Mouse running performance
- Extended
- Healthspan
- The strongest support for the 'exercise mimetic' framing: exercise itself increases MOTS-c in human muscle and circulation.
- Treated mice improved physical capacity and running performance across young, middle-aged and old groups, not just in the aged cohort.
- The human component is observational — it shows the peptide responds to exercise, not that supplementing it improves human performance.
MOTS-c reduces myostatin and muscle atrophy signalling
How MOTS-c interacts with the signalling that drives muscle wasting.
Am J Physiol Endocrinol Metab · human plasma MOTS-c vs myostatin correlation · diet-induced obese mice · FOXO1, AKT/mTORC2 and atrophy endpoints
- Inverse to myostatin
- Human plasma correlation
- Suppressed
- Myostatin in obese mice
- FOXO1 down, AKT/mTORC2 up
- Pathways
- Establishes an inverse relationship in humans between circulating MOTS-c and myostatin, the protein that restrains muscle growth.
- In diet-induced obese mice the peptide suppressed myostatin, inhibited FOXO1 transcription and activated AKT/mTORC2 to prevent wasting.
- The human element is a correlation only; the causal work is entirely rodent.
Metabolic disease & cellular ageing
MOTS-c prevents pancreatic islet cell senescence and glucose intolerance
Whether MOTS-c can act on the cell ageing that underlies declining glucose control.
Experimental & Molecular Medicine (Nature Portfolio) · circulating MOTS-c in type 2 diabetes patients vs healthy controls · multiple rodent models · islet senescence and glucose tolerance endpoints
- Circulating MOTS-c reduced
- Type 2 diabetes patients
- Reversed in rodents
- Islet senescence
- Improved
- Glucose tolerance
- Confirms that circulating MOTS-c drops meaningfully in people with type 2 diabetes compared with healthy controls.
- In rodents it behaved as a senotherapeutic agent — reversing cell ageing in the pancreatic islets rather than only improving glucose handling downstream.
- The effect held across multiple rodent models, which strengthens it, but no human treatment arm was involved.
MOTS-c improves intrinsic muscle mitochondrial bioenergetic performance
What MOTS-c does to mitochondrial efficiency and oxidative stress, and where circulating MOTS-c actually comes from.
Free Radical Biology and Medicine · mitochondrial respiration and ROS emission assays · one-legged exercise protocol in humans tracking local versus systemic MOTS-c
- Improved via PGC-1α / AMPK
- Mitochondrial performance
- Substantially reduced
- ROS emission
- Likely not skeletal muscle
- Systemic source
- Improves intrinsic mitochondrial performance while lowering reactive oxygen species and oxidative damage — efficiency gains rather than simply more output.
- The one-legged exercise design is the clever part: local muscle MOTS-c rose in the exercised leg, but the MOTS-c entering general circulation appears to originate elsewhere.
- That finding complicates the assumption that muscle is the main systemic source, and reopens the question of which tissue is.
Active human clinical trials
MOTS-c for improving insulin sensitivity in prediabetes and overweight/obesity
The first registered trial testing MOTS-c itself for metabolic endpoints in humans.
Randomised, double-blind, placebo-controlled · sponsored by Hudson Biotech · 12-week treatment period · adults with prediabetes and overweight/obesity · insulin sensitivity, HbA1c, fasting glucose and cardiovascular markers
- No results have been reported. Nothing here should be read as evidence of human effect yet.
- It is the readout that matters most for the compound, because every current metabolic finding is rodent or correlational.
- Earlier human work came from CohBar's phase 1a/1b safety testing of the MOTS-c analog CB4211 in obesity and fatty liver disease, not MOTS-c itself.
Storage & handling
MOTS-c is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water directed slowly down the inner wall of the vial and swirl gently until clear. Do not shake.
Store reconstituted solution at 2-8 °C and use within the stability window set by your lab's standard operating procedures.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.